2011
DOI: 10.1007/s11060-011-0681-7
|View full text |Cite
|
Sign up to set email alerts
|

Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma

Abstract: The purpose of this study is to evaluate the efficacy and toxicity of radiation therapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG). Newly diagnosed patients younger than 18 years with histologically proven DIPG were treated with focal radiotherapy to a dose of 54 Gy in 30 fractions along with concurrent daily TMZ (75 mg/m(2)/day). Four weeks after completing the initial RT-TMZ schedule, adjuvant TMZ (200 mg/m(2)/day, da… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
55
0
4

Year Published

2012
2012
2023
2023

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 115 publications
(59 citation statements)
references
References 34 publications
0
55
0
4
Order By: Relevance
“…This is one condition where no pathological confirmation is necessary for the start of radiotherapy treatment 2. The prognosis remains poor irrespective of the treatment, with a mean survival of 9–12 months 3.…”
Section: Discussionmentioning
confidence: 99%
“…This is one condition where no pathological confirmation is necessary for the start of radiotherapy treatment 2. The prognosis remains poor irrespective of the treatment, with a mean survival of 9–12 months 3.…”
Section: Discussionmentioning
confidence: 99%
“…[38]. Добавление к ЛТ различных видов ХТ, в том числе ТЗМ, как видно из доступных публикаций [39][40][41][42], не привело к улучшению пока-зателей выживаемости и БРТ, а в некоторых случаях сопровождалось миелотоксическими осложнениями. Лучевая терапия сегодня остается единственным ме-тодом, позволяющим стабилизировать рост опухоли.…”
Section: темозоломид при диффузно растущих опухолях ствола мозгаunclassified
“…The association of Chemotherapy (ChT) and radiotherapy (RT) have not improved survival 1,[6][7][8]10,11 and now biologics are combined with RT in clinical trials. 9,12,13 We investigated the association of RT with Nimotuzumab, a humanized monoclonal antibody developed at the Center of Molecular Immunology, Havana, Cuba and testing the hypothesis that this combination will improve survival in these tumors.…”
Section: 9mentioning
confidence: 99%